A Two Part, Randomized Clinical Trial to Study Biomarkers of MK-8237 (SCH 900237) Treatment in Subjects With House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis

Trial Profile

A Two Part, Randomized Clinical Trial to Study Biomarkers of MK-8237 (SCH 900237) Treatment in Subjects With House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 06 Mar 2017 Results (n=23) presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 14 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Jun 2015 Planned End Date changed from 1 Sep 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top